You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》榮昌生物製藥(09995.HK)料治療紅斑狼瘡新藥快將獲批上市
阿思達克 10-27 18:07
內地生物製藥公司榮昌生物製藥(09995.HK)公布在聯交所主板上市計劃,公司預料其研發治療系統性紅斑狼瘡的核心候選藥物「泰它西普」快將獲批上市。公司董事長及執行董事王威東在網上記者會表示,該藥推出市場的價格定位會考慮患者負擔能力,及參考主要競爭對手的定價,長遠而言希望該新藥可早日進入國家醫保名錄。

對於公司是次招股與螞蟻集團(06688.HK)撞期,首席執行官兼首席科學官房健民指是次上市是跟隨公司自己的節奏,公司亦獲得很多基石投資者支持,對股份成功發行有信心。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account